



# SARS SPIKE blocking peptide (CDBP6057)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

|               |                                                            |
|---------------|------------------------------------------------------------|
| Conjugate     | Unconjugated                                               |
| Applications  | Used as a blocking peptide in immunoblotting applications. |
| Format        | Liquid                                                     |
| Concentration | 200 µg/mL                                                  |
| Size          | 0.05 mg                                                    |
| Preservative  | None                                                       |
| Storage       | -20°C                                                      |

## BACKGROUND

|              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|--------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Introduction | The SARS coronavirus, sometimes shortened to SARS-CoV, is the virus that causes severe acute respiratory syndrome (SARS). On April 16, 2004, following the outbreak of SARS in Asia and secondary cases elsewhere in the world.                                                                                                                                                                                                                                                                                                          |
| Keywords     | SARS Spike (IN1); SARS; E2; E2 glycoprotein; Human coronavirus spike glycoprotein; Peplomer protein; S; S glycoprotein; Severe acute respiratory syndrome spike glycoprotein; Severe acute respiratory syndrome virus spike glycoprotein; Spike glycoprotein; VGL2; Group IV; Nidovirales; Coronaviridae; Coronavirus; SARS coronavirus; SARS Spike (IN2); SARS Spike (IN3); SARS Spike (CT); SARS Spike Protein; SARS spike glycoprotein; SARS Spike Protein (Middle); SARS (Severe Acute Respiratory Syndrome) Spike protein (Middle); |